Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
XAIR Stock Summary
Top 10 Correlated ETFs
XAIR
In the News
Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?
Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.43 per share a year ago.
Beyond Air, Inc. (XAIR) Q2 2024 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jeremy Jacoby - Truist Securities Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended September 30, 2023. At this time, participants are in a listen-only mode.
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts. Abstracts are scheduled to be released to AACR-NCI-EORTC registrants today 12:00 pm U.S. ET.
3 Top Penny Stocks To Buy Now According To Insiders In August
The realm of penny stocks, often characterized by their affordable price tag, has become a hotspot for investors eager to seize the stock market's opportunities. These stocks, typically valued under $5, carry inherent risks and promise impressive rewards.
Beyond Air, Inc. (XAIR) Q1 2024 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Marie Thibault - BTIG Scott Henry - ROTH Capital Jason Bednar - Piper Sandler Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended June 30, 2023. At this time, all participants are in a listen-only mode.
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.37 per share a year ago.
Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.
XAIR Financial details
XAIR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.91 | 0.12 | 0.05 | 0 | 0 | |
Net income per share | -0.77 | -1.73 | -1.27 | -1.68 | -1.86 | |
Operating cash flow per share | 0.16 | -1.33 | -1.09 | -0.9 | -1.1 | |
Free cash flow per share | 0.15 | -1.33 | -1.14 | -0.96 | -1.23 | |
Cash per share | 0.93 | 1.72 | 1.92 | 3.13 | 1.53 | |
Book value per share | 0.47 | 1.57 | 1.69 | 2.83 | 1.26 | |
Tangible book value per share | 0.42 | 1.54 | 1.67 | 2.98 | 1.35 | |
Share holders equity per share | 0.47 | 1.57 | 1.69 | 2.83 | 1.26 | |
Interest debt per share | 0.03 | 0.43 | 0.42 | 0.17 | 0.12 | |
Market cap | 39.94M | 92.05M | 99.03M | 171.46M | 202.32M | |
Enterprise value | 38.87M | 77.1M | 71.33M | 94.71M | 176.76M | |
P/E ratio | -6.09 | -4.62 | -4.33 | -3.97 | -3.62 | |
Price to sales ratio | 5.17 | 66.22 | 113.43 | 0 | 0 | |
POCF ratio | 29.78 | -6.04 | -5.04 | -7.41 | -6.13 | |
PFCF ratio | 31.09 | -6.02 | -4.82 | -6.97 | -5.49 | |
P/B Ratio | 9.92 | 5.09 | 3.25 | 2.36 | 5.34 | |
PTB ratio | 9.92 | 5.09 | 3.25 | 2.36 | 5.34 | |
EV to sales | 5.03 | 55.46 | 81.71 | 0 | 0 | |
Enterprise value over EBITDA | -12.97 | -4.29 | -3.24 | -3.2 | -3.47 | |
EV to operating cash flow | 28.98 | -5.06 | -3.63 | -4.09 | -5.35 | |
EV to free cash flow | 30.26 | -5.04 | -3.47 | -3.85 | -4.79 | |
Earnings yield | -0.16 | -0.22 | -0.23 | -0.25 | -0.28 | |
Free cash flow yield | 0.03 | -0.17 | -0.21 | -0.14 | -0.18 | |
Debt to equity | 0.07 | 0.27 | 0.23 | 0.05 | 0.09 | |
Debt to assets | 0.03 | 0.18 | 0.17 | 0.04 | 0.05 | |
Net debt to EBITDA | 0.36 | 0.83 | 1.26 | 2.59 | 0.5 | |
Current ratio | 1.61 | 5.46 | 9.8 | 8.68 | 3 | |
Interest coverage | -2.03K | -593.98 | -34.6 | -52.53 | -1.72K | |
Income quality | -0.2 | 0.76 | 0.86 | 0.53 | 0.56 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.89 | 6.39 | 11.99 | 0 | 0 | |
Research and developement to revenue | 0.51 | 7.66 | 14.45 | 0 | 0 | |
Intangibles to total assets | 0.05 | 0.02 | 0.01 | 0.02 | 0.02 | |
Capex to operating cash flow | -0.04 | 0 | 0.05 | 0.06 | 0.12 | |
Capex to revenue | -0.01 | -0.03 | -1.02 | 0 | 0 | |
Capex to depreciation | -0.87 | -0.27 | -4.22 | -2.46 | -3.31 | |
Stock based compensation to revenue | 0.31 | 2.57 | 5.61 | 0 | 0 | |
Graham number | 2.87 | 7.83 | 6.95 | 10.35 | 7.28 | |
ROIC | -0.71 | -0.78 | -0.58 | -0.52 | -1.1 | |
Return on tangible assets | -0.73 | -0.74 | -0.57 | -0.44 | -0.83 | |
Graham Net | 0.33 | 1.2 | 1.44 | 2.33 | 0.67 | |
Working capital | 3.29M | 21.74M | 33.42M | 82.23M | 39.63M | |
Tangible asset value | 3.53M | 17.68M | 30.09M | 76.37M | 40.4M | |
Net current asset value | 3.29M | 17.27M | 27.16M | 71.96M | 32.69M | |
Invested capital | 0.07 | 0.27 | 0.23 | 0.05 | 0.09 | |
Average receivables | 23.94K | 86.01K | 295.06K | 535K | 627.5K | |
Average payables | 1M | 1.71M | 1.79M | 1.23M | 1.57M | |
Average inventory | 319.47K | 3.58M | 4.2M | 1.12M | 739.5K | |
Days sales outstanding | 2.26 | 32.59 | 194.83 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 1.33K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 742.5 | |
Receivables turnover | 161.29 | 11.2 | 1.87 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0.28 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0.49 | |
ROE | -1.63 | -1.1 | -0.75 | -0.59 | -1.47 | |
Capex per share | -0.01 | 0 | -0.05 | -0.06 | -0.13 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q2
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.01 | |
Net income per share | -0.4 | -0.43 | -0.66 | -0.45 | -0.51 | |
Operating cash flow per share | -0.31 | -0.28 | -0.28 | -0.55 | -0.45 | |
Free cash flow per share | -0.34 | -0.31 | -0.34 | -0.57 | -0.5 | |
Cash per share | 2.09 | 1.78 | 1.5 | 1.82 | 1.22 | |
Book value per share | 1.97 | 1.7 | 1.24 | 1.13 | 0.81 | |
Tangible book value per share | 2.07 | 1.8 | 1.32 | 1.2 | 0.86 | |
Share holders equity per share | 1.97 | 1.7 | 1.24 | 1.13 | 0.81 | |
Interest debt per share | 0.1 | 0.1 | 0.11 | 0.54 | 0.56 | |
Market cap | 222.45M | 194.19M | 207.08M | 133.69M | 73.46M | |
Enterprise value | 195.57M | 171.54M | 181.51M | 119.2M | 77.08M | |
P/E ratio | -4.65 | -3.81 | -2.57 | -2.37 | -1.13 | |
Price to sales ratio | 0 | 0 | 0 | 2.27K | 307.36 | |
POCF ratio | -24.13 | -22.82 | -24.54 | -7.79 | -5.13 | |
PFCF ratio | -21.85 | -21.24 | -19.79 | -7.45 | -4.59 | |
P/B Ratio | 3.78 | 3.81 | 5.46 | 3.77 | 2.85 | |
PTB ratio | 3.78 | 3.81 | 5.46 | 3.77 | 2.85 | |
EV to sales | 0 | 0 | 0 | 2.02K | 322.5 | |
Enterprise value over EBITDA | -15.9 | -12.77 | -13 | -7.69 | -4.53 | |
EV to operating cash flow | -21.21 | -20.16 | -21.51 | -6.95 | -5.38 | |
EV to free cash flow | -19.21 | -18.76 | -17.35 | -6.64 | -4.82 | |
Earnings yield | -0.05 | -0.07 | -0.1 | -0.11 | -0.22 | |
Free cash flow yield | -0.05 | -0.05 | -0.05 | -0.13 | -0.22 | |
Debt to equity | 0.05 | 0.06 | 0.09 | 0.48 | 0.65 | |
Debt to assets | 0.04 | 0.04 | 0.05 | 0.23 | 0.29 | |
Net debt to EBITDA | 2.19 | 1.69 | 1.83 | 0.94 | -0.21 | |
Current ratio | 6.47 | 5.69 | 3 | 5.27 | 3.78 | |
Interest coverage | -262.94 | -304.57 | 119.95 | -100.47 | -19.18 | |
Income quality | 0.72 | 0.62 | 0.4 | 1.14 | 0.82 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 185.36 | 42.72 | |
Research and developement to revenue | 0 | 0 | 0 | 79.58 | 29.83 | |
Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | |
Capex to operating cash flow | 0.1 | 0.07 | 0.24 | 0.05 | 0.12 | |
Capex to revenue | 0 | 0 | 0 | -13.47 | -7.04 | |
Capex to depreciation | -4.08 | -1.79 | -5.95 | -1.76 | -3.31 | |
Stock based compensation to revenue | 0 | 0 | 0 | 103.64 | 27.03 | |
Graham number | 4.21 | 4.04 | 4.28 | 3.38 | 3.05 | |
ROIC | -0.19 | -0.23 | -0.28 | -0.27 | -0.38 | |
Return on tangible assets | -0.15 | -0.18 | -0.3 | -0.2 | -0.29 | |
Graham Net | 1.5 | 1.19 | 0.66 | 0.77 | 0.33 | |
Working capital | 63.48M | 54.42M | 39.63M | 51.35M | 34.68M | |
Tangible asset value | 61.92M | 53.76M | 40.4M | 37.56M | 27.3M | |
Net current asset value | 56.69M | 47.5M | 32.69M | 29.46M | 17.96M | |
Invested capital | 0.05 | 0.06 | 0.09 | 0.48 | 0.65 | |
Average receivables | 514K | 495.5K | 614K | 666.5K | 555K | |
Average payables | 1.52M | 1.71M | 1.71M | 1.88M | 2.52M | |
Average inventory | 698.5K | 833K | 1.04M | 1.23M | 1.46M | |
Days sales outstanding | 0 | 0 | 0 | 1.04K | 161.17 | |
Days payables outstanding | 1.01K | 1.87K | 589.09 | 516.24 | 685.83 | |
Days of inventory on hand | 357.49 | 1.26K | 329.9 | 397.72 | 327.92 | |
Receivables turnover | 0 | 0 | 0 | 0.09 | 0.56 | |
Payables turnover | 0.09 | 0.05 | 0.15 | 0.17 | 0.13 | |
Inventory turnover | 0.25 | 0.07 | 0.27 | 0.23 | 0.27 | |
ROE | -0.2 | -0.25 | -0.53 | -0.4 | -0.63 | |
Capex per share | -0.03 | -0.02 | -0.07 | -0.03 | -0.05 |
XAIR Frequently Asked Questions
What is Beyond Air, Inc. stock symbol ?
Beyond Air, Inc. is a US stock , located in Garden city of Ny and trading under the symbol XAIR
What is Beyond Air, Inc. stock quote today ?
Beyond Air, Inc. stock price is $1.73 today.
Is Beyond Air, Inc. stock public?
Yes, Beyond Air, Inc. is a publicly traded company.